Education Weekend

Fifty families came together for the 2019 Education Weekend, which was held at Seven Springs Mountain Resort, March 23-24.

Saturday was packed with programming. There was something for everyone. Topics included children with bleeding disorders; women and girls with bleeding disorders; musculoskeletal ultrasound; understanding addictions; camp for children with bleeding disorders; medical marijuana; first-aid; insurance; and more! Session sponsors included Takeda, Aptevo, CSL Behring, Hemophilia Federation of America, and Sanofi Genzyme.

Children participated in activities and programs, based on their age. Special programming for children included a Blood Buddies program and Comic Book Writing Workshop, sponsored by Diplomat Pharmacy; a Jr. Scientist program, sponsored by Accredo; and a Cookie Lab, sponsored by Octapharma. The teenagers attended an incredible Leading Edge program, run by GutMonkey and sponsored by Pfizer.

Saturday ended with an optional Jam Session, which was a lot of fun! We certainly have talented people in our Chapter. A couple of (Continued on next page)
(Continued from previous page)

people even performed songs that they composed themselves!

Sunday morning we wrapped up the weekend with a choice of four sessions: Infusion Day, Rare Bleeding Disorders, von Willebrand Disease, and Ask the Physical Therapist.

We thank the following for sponsoring this event:

**Title Sponsor**
Takeda

**Presenting Sponsors**
CSL Behring
Hemophilia Center of Western PA
Novo Nordisk
Pfizer
Sanofi Genzyme

**Supporting Sponsors**
Accredo
Aptivo
Cottrill’s Pharmacy
CVS Specialty
Diplomat
Drugco Health
Genentech
Octapharma
Spark Therapeutics

**References:**

For people with hemophilia, Factor treatment temporarily replaces what’s missing. With a long track record of proven results, Factor treatment works with your body’s natural blood clotting process to form a proper clot. Brought to you by Takeda, dedicated to pursuing advancements in hemophilia for more than 70 years.

Stay empowered by the possibilities.
Letter from the Interim Executive Director

Dear Chapter Members and Friends,

Happy Spring! It has been a busy few months for the Chapter as we continue to plan events and actively advocate for the community. Thank you so much to everyone who has volunteered, fundraised, attended events, and supported the Chapter so far this year.

The Bowling for Bleeding Disorders event was a great success! The event sold out and raised over $11,000 for the bleeding disorders community. Thank you so much to everyone who attended and made this event great!

Education Weekend at Seven Springs went off without a hitch. I hope everyone who was able to attend had a great time and came back with a wealth of information. Thank you to Janet and Jessica and the amazing volunteers who put countless hours into making this educational event a success.

As many of you know, I am off on maternity leave. My son, August Samuel, was born on March 23rd. I am absolutely thrilled to begin this new journey as a mother. I will be officially back from leave in July but will be checking e-mail regularly if you need to get in touch with me. Janet and Jessica will also be available to assist you and answer any questions you may have.

Thank you for all that you do on behalf of the bleeding disorders community.

Sincerely,

Kara Dornish
Interim Executive Director

Advocacy Update

In early January, the Eastern and Western PA Chapters traveled to Harrisburg to meet with representatives from the Appropriations Committees for the House Republicans and Democrats as well as the Senate Republicans and Democrats. In addition, there were meetings with Sarah Boating, Executive Deputy Secretary for the Department of Health and Jen Swails, Budget Deputy Secretary for the Department of Health and Human Services. Our discussions focused on the Hemophilia Program, which once again was combined with other line items in the Governor's proposed 2019-2020 budget.

Governor Wolf was sent letters supporting the Hemophilia Program as a separate line item with at least level funding from Representative Thomas Mehaffie, III, Senator Tom Killion, Representative Mary Louise Isaacson, Representative Dan Frankel (Chairman-Democratic Health Committee) and Senator Lawrence Farnese, Jr. More letters will be coming.

In addition, Senator Jay Costa and Representative Maureen Madden are sponsoring a resolution recognizing March, 2019 as “Bleeding Disorders Awareness Month” in Pennsylvania. Senator Costa and Representative Frankel are sponsoring a resolution recognizing April 17, 2019 as “World Hemophilia Day.”

The Chapter is always raising funds for our educational programs and member support activities, but sometimes we just need a few small things for the office. WPCNHF has a list of items needed in the office. If you, or anyone you know, is interested in donating any of the following please contact the office at info@wpcnhf.org or call us at 724-741-6160.

- White copy paper by the ream or by the case
- Sticky Notes
- Forever U.S. Postage stamps
- 10 x 13 Ready-seal envelopes for newsletter mailings
- 10 x 13 Envelope Mailing Stamps
- Magic markers
- On sale for $3.00 per pack (6 pkts)
- Mark your calendars for the 3rd Annual Hemogram
- Black and white copier

WPCNHF Wish List

The Chapter is always raising funds for our educational programs and member support activities, but sometimes we just need a few small things for the office. WPCNHF has a list of items needed in the office. If you, or anyone you know, is interested in donating any of the following please contact the office at info@wpcnhf.org or call us at 724-741-6160.

- White copy paper by the ream or by the case
- Sticky Notes
- Forever U.S. Postage stamps
- 10 x 13 Ready-seal envelopes for newsletter mailings
- 10 x 13 Envelope Mailing Stamps
- Magic markers
- On sale for $3.00 per pack (6 pkts)
- Mark your calendars for the 3rd Annual Hemogram
- Black and white copier

Calender of Upcoming Events

<table>
<thead>
<tr>
<th>Event Name</th>
<th>Date</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Meeting &amp; Walk Kickoff</td>
<td>July 25, 2019</td>
<td>Homestead, PA</td>
</tr>
<tr>
<td>Pittsburgh, PA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Parent Network</td>
<td>November 2, 2019</td>
<td>Pittsburgh, PA</td>
</tr>
<tr>
<td>Oakland, PA</td>
<td>November 16, 2019</td>
<td>Oakland, PA</td>
</tr>
<tr>
<td>Camp Hot-to-Cot</td>
<td>August 4-10, 2019</td>
<td>Fombell, PA</td>
</tr>
<tr>
<td>Winterfest</td>
<td>December 8, 2019</td>
<td>Oakland, PA</td>
</tr>
<tr>
<td>Camp Hot-to-Cot</td>
<td>August 4-10, 2019</td>
<td>Fombell, PA</td>
</tr>
<tr>
<td>Winterfest</td>
<td>December 8, 2019</td>
<td>Oakland, PA</td>
</tr>
<tr>
<td>HFA Symposium</td>
<td>April 4-7, 2019</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>United for Bleeding Disorders Conference</td>
<td>April 9, 2019</td>
<td>Anaheim, CA</td>
</tr>
<tr>
<td>New Parent Network</td>
<td>November 2, 2019</td>
<td>Pittsburgh, PA</td>
</tr>
<tr>
<td>Pittsburgh, PA</td>
<td>November 16, 2019</td>
<td>Oakland, PA</td>
</tr>
<tr>
<td>Cornhole Tournament</td>
<td>April 6, 2019</td>
<td>Oakdale, PA</td>
</tr>
<tr>
<td>Run for Their Lives 5K</td>
<td>September 7, 2019</td>
<td>Allison Park, PA</td>
</tr>
<tr>
<td>Pittsburgh, PA</td>
<td>October 3-5, 2019</td>
<td>Allison Park, PA</td>
</tr>
<tr>
<td>Annual Meeting &amp; Walk Kickoff</td>
<td>July 25, 2019</td>
<td>Homestead, PA</td>
</tr>
<tr>
<td>Pittsburgh, PA</td>
<td>October 24, 2019</td>
<td>Pittsburgh, PA</td>
</tr>
<tr>
<td>Women’s Group</td>
<td>November 2, 2019</td>
<td>Pittsburgh, PA</td>
</tr>
<tr>
<td>Pittsburgh, PA</td>
<td>November 16, 2019</td>
<td>Oakland, PA</td>
</tr>
<tr>
<td>Run for Their Lives 5K</td>
<td>September 7, 2019</td>
<td>Allison Park, PA</td>
</tr>
<tr>
<td>Pittsburgh, PA</td>
<td>October 3-5, 2019</td>
<td>Allison Park, PA</td>
</tr>
<tr>
<td>Annual Meeting &amp; Walk Kickoff</td>
<td>July 25, 2019</td>
<td>Homestead, PA</td>
</tr>
<tr>
<td>Pittsburgh, PA</td>
<td>October 24, 2019</td>
<td>Pittsburgh, PA</td>
</tr>
</tbody>
</table>

Letter to the Interim Executive Director

Dear Chapter Members and Friends,

Education Weekend at Seven Springs went off without a hitch. I hope everyone who was able to attend had a great time and came back with a wealth of information. Thank you to Janet and Jessica and the amazing volunteers who put countless hours into making this educational event a success.

As many of you know, I am off on maternity leave. My son, August Samuel, was born on March 23rd. I am absolutely thrilled to begin this new journey as a mother. I will be officially back from leave in July but will be checking e-mail regularly if you need to get in touch with me. Janet and Jessica will also be available to assist you and answer any questions you may have.

Thank you for all that you do on behalf of the bleeding disorders community.

Sincerely,

Kara Dornish
Interim Executive Director

Advocacy Update

In early January, the Eastern and Western PA Chapters traveled to Harrisburg to meet with representatives from the Appropriations Committees for the House Republicans and Democrats as well as the Senate Republicans and Democrats. In addition, there were meetings with Sarah Boating, Executive Deputy Secretary for the Department of Health and Jen Swails, Budget Deputy Secretary for the Department of Health. Our discussions focused on the Hemophilia Program, which once again was combined with other line items in the Governor’s proposed 2019-2020 budget.

Governor Wolf was sent letters supporting the Hemophilia Program as a separate line item with at least level funding from Representative Thomas Mehaffie, III, Senator Tom Killion, Representative Mary Louise Isaacson, Representative Dan Frankel (Chairman-Democratic Health Committee) and Senator Lawrence Farnese, Jr. More letters will be coming.

In addition, Senator Jay Costa and Representative Maureen Madden are sponsoring a resolution recognizing March, 2019 as “Bleeding Disorders Awareness Month” in Pennsylvania. Senator Costa and Representative Frankel are sponsoring a resolution recognizing April 17, 2019 as “World Hemophilia Day.”

March, 2019 as “Bleeding Disorders Awareness Month” in Pennsylvania. Senator Costa and Representative Frankel are sponsoring a resolution recognizing April 17, 2019 as “World Hemophilia Day.”

WPCNHF Mission Statement:

WPCNHF strives to enrich the lives of those with bleeding disorders in Western Pennsylvania and respond to the needs of the community in a dynamic environment.

WPCNHF Wish List

The Chapter is always raising funds for our educational programs and member support activities, but sometimes we just need a few small things for the office. WPCNHF has a list of items needed in the office. If you, or anyone you know, is interested in donating any of the following please contact the office at info@wpcnhf.org or call us at 724-741-6160.

- White copy paper by the ream or by the case
- Sticky Notes
- Forever U.S. Postage stamps
- 10 x 13 Ready-seal envelopes for newsletter mailings
- 10 x 13 Envelope Mailing Stamps
- Magic markers
- On sale for $3.00 per pack (6 pkts)
- Mark your calendars for the 3rd Annual Hemogram
- Black and white copier

Combined Federal Campaign

WPCNHF is an approved charitable organization for the Combined Federal Campaign (CFC). If you participate in the CFC, please consider designating all or a portion of your donation to the Chapter.

WPCNHF CFC Number is: 81343
Warm Wishes from your HCWP:

It was wonderful to spend time with so many of you at the Chapter’s Education Weekend in Seven Springs. The educational content, networking, and relationship building was so impactful, and we at the Center were grateful to be a part of it.

Our Amish Outreach Clinics will begin in April and go through May. We are getting closer to camp registration time beginning May 1st and going through June 30th. Please make sure you pay attention to those deadlines! It’s a great time to call and get those annual clinics scheduled in anticipation of summer months. Our teens that are approaching graduation and considering post-secondary plans should look to the NHF website and contact your local HTC social worker to investigate the available scholarships.

Thank you to all of our patients who continue to give us feedback via the patient satisfaction surveys distributed in clinic. Please know that we also have a Consumer Advocacy Committee that meets three times per year. It offers patients, parents, and caretakers the opportunity to voice their concerns, challenges, and suggestions to the HCWP staff regarding programs and patient care issues. Please contact Katherine or Kathaleen at the Center if you would like to participate.

Let’s get together to talk about IXINITY*

After many years, I am still so inspired by the strength and sense of family in the bleeding disorder community. It brings me great joy to be a part of it!
—Ellen Rowe, your resource for all things IXINITY

Contact Ellen at 215-908-4276 or rowee@apvo.com

IXINITY® coagulation factor IX (recombinant)

IXINITY® is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about IXINITY?

IXINITY® increases the potential for your blood to clot. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. IXINITY® may cause serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including thrombotic microangiopathy (TMA), and blood clots (thrombotic events). If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

Please see Brief Summary of Medication Guide on following page for Important Safety Information, including Serious Side Effects.

HEMLIBRA® increases the potential for your blood to clot. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. HEMLIBRA® may cause serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including thrombotic microangiopathy (TMA), and blood clots (thrombotic events). If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

Please see Brief Summary of Medication Guide on following page for Important Safety Information, including Serious Side Effects.

HEMLIBRA® is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. HEMLIBRA® may cause serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including thrombotic microangiopathy (TMA), and blood clots (thrombotic events). If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

Please see Brief Summary of Medication Guide on following page for Important Safety Information, including Serious Side Effects.
HEMLIBRA® (hem-lee-bruh) (emicizumab-kxwh)

HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
The HEMLIBRA logo is a trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.

The Genentech logo is a registered trademark of Genentech, Inc.
All other trademarks are the property of their respective owners.

The Sixth Annual Bowling for Bleeding Disorders fundraiser was held at Paradise Island Bowl in Neville Island, Pennsylvania on Sunday, February 17, 2019. The cost to attend was $25 per participant which included an event t-shirt, shoe rental, bowling, pizza, wings, and unlimited soft drinks.

All 16 lanes were filled as 75 bowlers competed for the prize of highest score and best style. Congratulations to Jay Ahrhart from team Ahrbats for Byrker who won the award for highest score!

We are extremely grateful for everyone who participated in this event. We are excited to report that over $11,000 was raised from this event! All of this money will go toward emergency and medical patient assistance, educational programs, and support groups to benefit the bleeding disorders community in Western PA. The sponsors of the event included The Hemophilia Center of Western Pennsylvania, CSL Behring, Novo Nordisk, Bayer, and 91.3 WYEP.

WPCNHF would like to thank all who participated in and sponsored this event. We can’t wait to see you at the next Bowling for Bleeding Disorders event coming soon!
Young Hope Society

On Thursday, January 24th the Western Pennsylvania Chapter of the National Hemophilia Foundation held its first Young Hope Society event at Top Golf in Bridgeville, PA. The Young Hope Society is a young professionals group that was created to inspire the next generation of young people to participate in national networking events with like-minded young professionals and industry experts and to learn more about the bleeding disorders community.

The Young Hope Society event at Top Golf in Pennsylvania Chapter of the National Hemophilia Foundation will be held in late June. The evening will begin with a reception, dinner, and a roundtable discussion with Dr. Frederico Xavier, Associate Director of the Hemophilia Center of Western PA, and Hematologist at Children’s Hospital of Pittsburgh. Dr. Xavier provided an overview of bleeding disorders and identifying bleeds, answered questions, and addressed many of the concerns parents of young children with bleeding disorders have. Childcare was provided, in a separate room, so the parents could participate and focus on the program.

The WPCNHF Youth Group held its first event at the Pittsburgh Zoo & PPG Aquarium. The night started off with a behind the scenes tour, which allowed us to see lions and tigers up close and learn more about them.

Next, everyone headed back outside and went on an investigative scavenger hunt to solve one more mystery! Back inside we had animal visits and close encounters with an armadillo, snake, and porcupine. Before departing the next day, three more animals came to visit us and we learned some fascinating facts about them.

The zoo overnight was a fun and unique experience and I’m sure that both the kids and the chaperones will remember it for a long time to come. We thank Delores Johnson Huber for suggesting the youth group event.

Based on the success of this event, we look forward to planning more in the future!

We thank Genentech, Sanoft Genzyme, and Takeda for sponsoring the 2019 New Parent Network series of events.

New Parent Network

The first program in the 2019 New Parent Network series of events was held on March 22, in Seven Springs, PA. New Parent Network programs are for families who have a child age six and under, with a bleeding disorder. The families attended dinner and a roundtable discussion with Dr. Frederico Xavier, Associate Director of the Hemophilia Center of Western PA, and Hematologist at Children’s Hospital of Pittsburgh. Dr. Xavier provided an overview of bleeding disorders and identifying bleeds, answered questions, and addressed many of the concerns parents of young children with bleeding disorders have. Childcare was provided, in a separate room, so the parents could participate and focus on the program.

The WPCNHF Youth Group held its first event at the Pittsburgh Zoo & PPG Aquarium. The night started off with a behind the scenes tour, which allowed us to see lions and tigers up close and learn more about them.

Next, everyone headed back outside and went on an investigative scavenger hunt to solve one more mystery! Back inside we had animal visits and close encounters with an armadillo, snake, and porcupine. Before departing the next day, three more animals came to visit us and we learned some fascinating facts about them.

The zoo overnight was a fun and unique experience and I’m sure that both the kids and the chaperones will remember it for a long time to come. We thank Delores Johnson Huber for suggesting the youth group event.

Based on the success of this event, we look forward to planning more in the future!

We thank Genentech, Sanoft Genzyme, and Takeda for sponsoring the 2019 New Parent Network series of events.
Thank you for participating in the Red Tie Campaign!

YETI
By Julia Shoemaker

I recently traveled to Oregon to attend the YETI (Youth Effectively Transitioning to Independence) conference. It was an amazing trip. It was the first time I flew on a plane and it was worth it. Everyone there was very kind and welcoming, even though I hardly knew anyone.

YETI is all about helping teenagers who are involved in the bleeding disorder community become independent and stay active in the community. It was also an opportunity to expand ourselves. We talked about how to build resumes, what to put on them, and what to maybe leave out. For example, YETI is a great thing to have on a resume. It shows that you took initiative and are a leader to others. However, it could also show that you are a part of the bleeding disorder community and may have a bleeding disorder. You may not want others to know that. In that case, you would just put YETI on the resume, and when you discuss it in an interview, you could state that it was a conference that built up leadership qualities.

We also learned how to communicate with others who have different personality types and communication preferences. For example, someone who may be more introverted may not want to communicate with others. However, when introverts try to discuss their opinions with another group of people, their opinions normally get pushed away because they are so quiet and shy. We learned that introverts should push themselves outside their comfort zone a little bit, so that they may grow a little bit and become better at communicating with others.

It was an educational weekend that felt like a vacation. It was a truly wonderful experience that I thank the Chapter for providing me.

[Julia is a high school junior and Co-Coordinator for our Teen Group. She is also a Leader-in-During training at Camp Hot-to-Chot. She attended YETI with Janet Barone, Member Services Manager (WPCNHF) and Activities Coordinator for Camp Hot-to-Chot, and Katherine Bush, Mental Health Professional (HCWP) and Co-Director for Camp Hot-to-Chot. YETI was hosted by the Hemophilia Foundation of Oregon.]

Who Makes the Decision?
By Derek L. Markley

It has been more than eight years since St. Jude's Children's Research Hospital, University College London, and the Royal Free Hospital began a clinical trial using gene therapy to treat people with hemophilia B.

That same year, our family welcomed a new baby, Bubba, who has severe hemophilia B. We had recently located to central Illinois from east Tennessee when I accepted a position with Eastern Illinois University. Bringing a new child into the world is a wonderful and stressful time for any family. As parents who had no experience with bleeding disorders, my wife and I were wholly unprepared for a hemophilia diagnosis.

Six months after Bubba was born, I was headed to lunch with a friend after meetings in the state capitol building. I can still tell you exactly where I was standing when my friend handed me her phone and asked if I'd seen the New York Times article about gene therapy and hemophilia B.

Fast forward a few years, and we again relocated, this time to Tupelo, Mississippi. We were very fortunate to become patients at St. Jude. Little did we know that Bubba’s physician would be one of the primary investigators in the gene therapy clinical trial. All of a sudden, the world of gene therapy was thrust directly in front of us.

We are now in a position, like many other hemophilia families, where the reality of a cure for hemophilia seems within reach. Currently, three phase III trials are beginning to test the efficacy of gene therapy in treating hemophilia B. Clinical research does not move quickly. But advancements in gene therapy over the past eight years have been amazing. The FDA has released new guidelines regarding gene therapy development, and funding for these ventures is in overdrive.

If gene therapy treatment becomes a reality, I’m forced to ask these questions: Is this a decision we can make for our son? Do the parents get to decide? How do we talk to our son about the risks and rewards of such a treatment? Bubba is only eight now, but it seems wise to begin thinking about how we’d handle this situation. Of course, the question is moot if insurers, treatment providers, and pharmaceutical companies can’t agree on a feasible reimbursement strategy. There are a lot of variables at play, yet the advancement of gene therapy treatment demands that Bubba’s mother and I begin thinking about how we will make decisions if a gene therapy treatment becomes available for our son.

It’s amazing that, all of the health conditions in our world, science and medicine have combined to put a treatment for our son's type of hemophilia at the forefront of gene therapy. Bubba is a very active kid. My wife describes him as “all boy.” His condition has done nothing to slow him down. Bumps, bruises, cuts, or scrapes, he weather them all and refuses to be limited by his uncooperative blood.

We’re reaching a time where Bubba’s questions about hemophilia have

Who Makes the Decision?
By Derek L. Markley

It has been more than eight years since St. Jude’s Children’s Research Hospital, University College London, and the Royal Free Hospital began a clinical trial using gene therapy to treat people with hemophilia B.

That same year, our family welcomed a new baby, Bubba, who has severe hemophilia B. We had recently located to central Illinois from east Tennessee when I accepted a position with Eastern Illinois University. Bringing a new child into the world is a wonderful and stressful time for any family. As parents who had no experience with bleeding disorders, my wife and I were wholly unprepared for a hemophilia diagnosis.

Six months after Bubba was born, I was headed to lunch with a friend after meetings in the state capitol building. I can still tell you exactly where I was standing when my friend handed me her phone and asked if I’d seen the New York Times article about gene therapy and hemophilia B.

Fast forward a few years, and we again relocated, this time to Tupelo, Mississippi. We were very fortunate to become patients at St. Jude. Little did we know that Bubba’s physician would be one of the primary investigators in the gene therapy clinical trial. All of a sudden, the world of gene therapy was thrust directly in front of us.

We are now in a position, like many other hemophilia families, where the reality of a cure for hemophilia seems within reach. Currently, three phase III trials are beginning to test the efficacy of gene therapy in treating hemophilia B. Clinical research does not move quickly. But advancements in gene therapy over the past eight years have been amazing. The FDA has released new guidelines regarding gene therapy development, and funding for these ventures is in overdrive.

If gene therapy treatment becomes a reality, I’m forced to ask these questions: Is this a decision we can make for our son? Do the parents get to decide? How do we talk to our son about the risks and rewards of such a treatment? Bubba is only eight now, but it seems wise to begin thinking about how we’d handle this situation. Of course, the question is moot if insurers, treatment providers, and pharmaceutical companies can’t agree on a feasible reimbursement strategy. There are a lot of variables at play, yet the advancement of gene therapy treatment demands that Bubba’s mother and I begin thinking about how we will make decisions if a gene therapy treatment becomes available for our son.

It’s amazing that, of all the health conditions in our world, science and medicine have combined to put a treatment for our son’s type of hemophilia at the forefront of gene therapy. Bubba is a very active kid. My wife describes him as “all boy.” His condition has done nothing to slow him down. Bumps, bruises, cuts, or scrapes, he weather them all and refuses to be limited by his uncooperative blood.

We’re reaching a time where Bubba’s questions about hemophilia have

The Hemophilia Center of Western Pennsylvania cloting factor program was established in 2000 as a complement to the Center’s other comprehensive care services. The clotting factor program allows the Center the opportunity to offer clotting factor to its patients, thereby supplementing its comprehensive treatment care model and providing the best possible care for its patients.

Please contact the Center at (412) 209-7280 for more information about how this program can benefit you and the entire bleeding disorder community.

The Hemophilia Center of Western Pennsylvania supports patient choice consistent with the Veterans Health Care Act of 1992 and maintains a freedom of choice policy where patients are informed of their choices regarding factor replacement products.

Factor Program Services
• All factor product brands available
• Online factor ordering available
• 24–48 hour delivery
• Same day courier service for emergent needs
• On-call services, 24/7
• Home treatment supplies
• Lot tracking for recall notification
• Online home treatment records
• Insurance benefit information assistance

Patient Benefits
• Direct communication and service from the Center’s treatment team
• Support of the Center’s operations
• Expansion of patient services

The Hemophilia Center of Western Pennsylvania clotting factor program was established in 2000 as a complement to the Center’s other comprehensive care services. The clotting factor program allows the Center the opportunity to offer clotting factor to its patients, thereby supplementing its comprehensive treatment care model and providing the best possible care for its patients.

Please contact the Center at (412) 209-7280 for more information about how this program can benefit you and the entire bleeding disorder community.

The Hemophilia Center of Western Pennsylvania supports patient choice consistent with the Veterans Health Care Act of 1992 and maintains a freedom of choice policy where patients are informed of their choices regarding factor replacement products.

Factor Program Services
• All factor product brands available
• Online factor ordering available
• 24–48 hour delivery
• Same day courier service for emergent needs
• On-call services, 24/7
• Home treatment supplies
• Lot tracking for recall notification
• Online home treatment records
• Insurance benefit information assistance

Patient Benefits
• Direct communication and service from the Center’s treatment team
• Support of the Center’s operations
• Expansion of patient services
What else should I know about ADVATE and Hemophilia A?

Do not attempt to infuse yourself with ADVATE unless you have been taught by your healthcare provider or hemophilia center. You must carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing ADVATE so that your treatment will work best for you.

What is the most important information I need to know about ADVATE?

Do not attempt to do an infusion to yourself unless you have been taught how by your healthcare provider or hemophilia center. You must carefully follow your healthcare provider’s instructions regarding the dose and schedule for infusing ADVATE so that your treatment will work best for you.

What should I tell my healthcare provider before I use ADVATE?

You should tell your healthcare provider if you:
- Have or have had any medical problems.
- Take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements or herbal remedies.
- Are allergic to mice or hamsters.
- Have any allergies, including allergies to ADVATE.
- Are breastfeeding.
- Are pregnant or breastfeeding ADVATE.
- Protect you from a bleeding event such as surgery, trauma or bleeding.

Who should not use ADVATE?

Who should use ADVATE?

You should use ADVATE if you:
- Are allergic to mice or hamsters.
- Are allergic to any ingredients in ADVATE.
- Are pregnant or breastfeeding.
- Have or have had any medical problems.
- Do not attempt to infuse yourself with ADVATE unless you have been taught how by your healthcare provider or hemophilia center.

How should I use ADVATE?

ADVATE is used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in people with hemophilia A (also called “classic” hemophilia). The product does not contain plasmas or albumins. Hemophilia A is an inherited bleeding disorder that prevents blood from clotting normally. ADVATE is used to prevent and control bleeding in adults and children (0-16 years) when used regularly (prophylaxis).

Important facts about ADVATE (Antithrombin Factor (Recombinant))

This leaflet summarizes important information about ADVATE. Please read it carefully before using this medicine. This information does not take the place of talking with your healthcare provider, and it does not include all of the important information about ADVATE. If you have any questions after reading this, ask your healthcare provider.

What are the possible side effects of ADVATE?

Advocate can reduce the number of bleeding episodes in adults and children (0-16 years) when used regularly (prophylaxis). ADVATE is not used to treat von Willebrand disease.

MyPKFiT for Patients Mobile Application offers visibility into your personalized ADVATE treatment. Talk to your doctor if you see if MyPKFiT for ADVATE may be right for you. Learn more at ADVATE.com.

The myPKFiT® for Patients Mobile Application offers visibility into your personalized ADVATE treatment. Talk to your doctor if you see if myPKFiT for ADVATE may be right for you. Learn more at ADVATE.com.

©2019 Shire U.S. Inc.; Lexington, MA 02421. All rights reserved. 1-800-929-1006. Labeled for the U.S. market. myPKFiT is a registered trademark of myPKFiT, Inc. The myPKFiT for Patients Mobile Application v2.0 User Manual. 2018.

The myPKFiT for Patients Mobile Application offers visibility into your personalized ADVATE treatment. Talk to your doctor if you see if myPKFiT for ADVATE may be right for you. Learn more at ADVATE.com.
INDICATIONS
• Jivi is an injectable medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A.
• Jivi is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older) with hemophilia A. Your healthcare provider may also give you Jivi when you have surgery. Jivi can reduce the number of bleeding episodes in adults and adolescents with hemophilia A when used regularly (prophylaxis).
• Jivi is not for use in children below 12 years of age or in previously untreated patients.
• Jivi is not used to treat von Willebrand disease.

IMPORTANT SAFETY INFORMATION
• You should not use Jivi if you are allergic to rodents (like mice and hamsters) or to any ingredients in Jivi.
• Tell your healthcare provider about all of your medical conditions that you have or had.
• Tell your healthcare provider if you have been told that you have inhibitors to Factor VIII.
• Allergic reactions may occur with Jivi. Call your healthcare provider right away if you get tightness of the chest or throat, dizziness, decrease in blood pressure, or hives.
• Allergic reactions to polyethylene glycol (PEG), a component of Jivi, are possible.
• Your body can also make antibodies, called “inhibitors,” against Jivi, which may stop Jivi from working properly. Consult your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to Factor VIII.

IMPORTANT SAFETY INFORMATION (CONT’D)
• If your bleeding is not being controlled with your usual dose of Jivi, consult your doctor immediately. You may have developed Factor VIII inhibitors or antibodies to PEG and your doctor may carry out tests to confirm this.
• The common side effects of Jivi are headache, cough, nausea, and fever.
• These are not all the possible side effects with Jivi. Tell your healthcare provider about any side effect that bothers you or that does not go away.

FEEL EMPOWERED to step up to the challenge with Jivi®

Ask your doctor if Jivi® may be right for you. Learn more at www.jivi.com.

IU, international units; kg, kilograms; rFVIII, recombinant Factor VIII.

Bayer, the Bayer Cross, and Jivi are registered trademarks of Bayer.
© 2019 Bayer. All rights reserved. Printed in USA 01/19 PP-JIV-US-0386-2
Who Makes the Decision?

If your bleeding is not being controlled with your usual dose of Jivi, consult your doctor immediately. You may have developed Factor VIII inhibitors or antibodies to PEG and your doctor may carry out tests to confirm this. These are not all the possible side effects with Jivi. You can ask your healthcare provider for information that is written for healthcare professionals. Tell your healthcare provider about any side effect that bothers you or that does not go away.

How do I store Jivi?

Do not freeze Jivi. Store Jivi at +2°C to +8°C (36°F to 46°F) for up to 24 months from the date of manufacture. Within this period, Jivi may be stored for a period of up to 6 months at temperatures up to +25°C or 77°F. Record the starting date of room temperature storage clearly on the unopened product carton. Once stored at room temperature, do not return the product to the refrigerator. The product then expires after storage at room temperature for 6 months, or after the expiration date on the product vial, whichever is earlier. Store vials in their original carton and protect them from extreme exposure to light. Administer reconstituted Jivi as soon as possible. If not, store at room temperature for no longer than 3 hours. Throw away any unused Jivi after the expiration date. Do not use reconstituted Jivi if it is not clear.

What else should I know about Jivi and hemophilia A?

Medicines are sometimes prescribed for purposes other than those listed here. Do not use Jivi for a condition for which it is not prescribed. Do not share Jivi with other people, even if they have the same symptoms that you have. This leaflet summarizes the most important information about Jivi that was written for healthcare professionals. Resources at Bayer available to the patient:

For Adverse Reaction Reporting, contact Bayer Medical Communications 1-888-84-BAYER (1-888-842-9297)

To receive more product information, contact Jivi Customer Service 1-888-606-3780

Bayer Reimbursement HELPLine 1-800-288-8374

For more information, visit http://www.Jivi.com

Bayer Healthcare LLC

Whippany, NJ 07981 USA

U.S. License No. 0008

It’s an exciting year for the WPCNHF’s Winning Women group. You might be asking yourself what is the WPCNHF’s Winning Women, what is its purpose, what can you expect from the group, and who is the person writing this article? Let’s start with the “who am I”, my name is Maria Steele Vorns Stein, I am a wife, a mother, a daughter, a friend, a full time working professional, volunteer, and I am a woman living with a bleeding disorder (VWD.)

The WPCNHF’s Winning Women group was formed to provide women affected by bleeding disorders with the education, support, skills and resources they need to advocate for their and/or their family’s healthcare, financial and social needs. The group is open to all women in our chapter, to include women diagnosed with bleeding disorders and/or an affected family member. Our programming includes valuable life skills, educational experiences that are independent of bleeding disorder diagnosis, and having a lot of fun! We’ve had some really exciting WPCNHF’s Winning Women events scheduled for 2019. Upcoming events dates: May 21st and October 24th, be sure to mark your calendars!

I encourage everyone to participate in WPCNHF’s Winning Women and other chapter events, as well as considering a role as a volunteer for chapter events. If you have ideas for future events or are interested in volunteering at any of the upcoming chapter events, please feel free to contact me at (412) 722-8539 or via e-mail at marias86@aol.com. I hope to see you at one of the WPCNHF’s Winning Women group events or other chapter event in the near future!
We Need Your Help!
There are many ways to participate in this event and we need your help! We need help acquiring donations, decorating trees and wreaths, and making the onsite event inviting, festive, and fun for all to enjoy.

How Can You Help?
1.) Volunteer - Volunteers are needed to help decorate trees and wreaths at the Chapter Office starting on November 1st. We will also need volunteers to help transport auction items from the Chapter Office to the Cornerstone at Tonidale and help set up on November 15th, as well as event day volunteers on November 16th.
2.) Donate - Donations of artificial trees and wreaths, holiday decor, gift cards, raffle basket items, and monetary donations are needed.
3.) Participate - Come and enjoy this fun and festive event! We invite you to attend this event and encourage you to invite your friends, family, and co-workers. It’s a great way to kick off your holiday season! We will also have all of the auction items available for bid online so even if you can’t attend the event in person we encourage you to participate in the online auction.

To sign up to volunteer or coordinate donation drop offs contact Kara at kara@wpcnhf.org